KBC Group
VERA icon

KBC Group’s Vera Therapeutics VERA Stock Holding History

KBC Group’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52K Sell
1,282
-670
-34% -$28.9K ﹤0.01% 1637
2025
Q4 		$99K Hold
1,952
– – ﹤0.01% 1290
2025
Q3 		$57K Buy
1,952
+1,250
+178% +$28.9K ﹤0.01% 1605
2025
Q2 		$17K Sell
702
-1,775
-72% -$39.9K ﹤0.01% 1709
2025
Q1 		$59K Hold
2,477
– – ﹤0.01% 1740
2024
Q4 		$105K Buy
2,477
+1,387
+127% +$61.4K ﹤0.01% 1525
2024
Q3 		$48K Hold
1,090
– – ﹤0.01% 1731
2024
Q2 		$39K Hold
1,090
– – ﹤0.01% 1742
2024
Q1 		$47K Buy
+1,090
New +$38.8K ﹤0.01% 1600

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KBC Group's VERA Position: Q1 2026 in Review

KBC Group reduced its Vera Therapeutics (VERA) stake by 34% in Q1 2026, selling an estimated $28.9K and leaving 1,282 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

KBC Group first reported a position in VERA in Q1 2024 and has held it in 9 quarters since. The position peaked at $105K in Q4 2024. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • KBC Group held 1,282 shares of Vera Therapeutics worth $52K as of Q1 2026.
  • KBC Group sold 670 Vera Therapeutics shares in Q1 2026, an estimated $28.9K.
  • Vera Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1637 holding.
  • KBC Group first reported a position in Vera Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • KBC Group's Vera Therapeutics position peaked at $105K in Q4 2024.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.